If you have been reading about evidence base and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-05. Numbers and descriptions here follow the published literature rather than marketing material.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
== Development == The mod was announced on March 6, 2014, by Coburn on Mod DB, citing the original Half-Life game and user-created mods as a reason to "give back to the community." Coburn stated that the mod was his "first real modding effort," creating a small campaign before expanding it during his spare time. The development took five years to complete before releasing on August 10. During the development, his child was born with a heart complication and required surgery at the Royal Hospital for Children, Glasgow and recovered. After the mod was complete, he requested all fans who wanted to donate to the hospital. The mod uses voice lines from the original Half-Life, as well as Half-Life: Opposing Force, Half-Life: Blue Shift, Half-Life: Decay, and Half-Life 2: Episode Two. On August 12, 2021, a team of developers announced a remake in Black Mesa called Black Mesa: Candidate Twelve after half a year in production. However this was confirmed to be on a hiatus in 2025 as they moved onto other projects.
== External links == Anatomy Atlases – Microscopic Anatomy, plate 01.05 Histology image: 22201loa – Histology Learning System at Boston University - "Ultrastructure of the Cell: chief cells and enteroendocrine cell" Histology image: 11304loa – Histology Learning System at Boston University - "Digestive System: Alimentary Canal: fundic stomach, gastric glands, base" "chief cell" at Dorland's Medical Dictionary Nosek, Thomas M. "Section 6/6ch4/s6ch4_8". Essentials of Human Physiology. Archived from the original on 2016-03-24.
=== Preparation of samples === Microtox can be applied to a variety of matrices including drinking water, stormwater runoff, effluent, industrial discharges, soils and sediments. Most samples do not require special preparation before testing besides adjusting the salinity to 2%. However, samples that have certain characteristics, such as high turbidity levels, may require special preparation. If samples require a salinity adjustment to lower the salinity, this can be accomplished by adding an appropriate amount of Microtox Osmotic Adjusting Solution to dilute the sample. For example, adding 0.1 mL of MOAS to 1 mL of sample would result in a dilution of 90.9% of the original concentration. If a greater salinity is required, this can be accomplished by dissolving solid sodium chloride in the sample to achieve a final salinity of 2% for the protection of Allivibrio fischeri. Highly turbid samples that contain particulate matter will be required to settle before the test can be conducted. Particulate matter in the sample can interfere with bioluminescence by absorbing light and give misleading test results. Interference of luminescence can also occur with samples which are highly colored (particularly red, brown or black). It may be necessary to centrifuge samples to obtain an acceptable clarity for the test. If samples contain chlorine, this may alter the toxicity to Allivibrio fischeri and also give misleading results. The samples can be de-chlorinated using a sodium thiosulphate and deionized water solution that does not affect test results.
HA and HA fragment-tumor cell interaction could activate the downstream signaling pathways, promoting cell proliferation, adhesion, migration and invasion, and inducing angiogenesis, lymphangiogenesis, epithelial-mesenchymal transition, stem cell-like property, and chemoradioresistance in digestive cancers.
PHF8: PHD finger protein 8 belongs to the family of ferrous iron and 2-oxoglutarate dependent oxygenases, and is a histone lysine demethylase with selectivity for the di-and monomethyl states. FMR2: Fragile mental retardation 2 (FMR2: synonym AFF2), the protein belongs to the AFF family which currently has four members: AFF1/AF4, AFF2/FMR2, AFF3/LAF4 and AFF4/AF5q31. All AFF proteins are localized in the nucleus and have a role as transcriptional activators with a positive action on RNA elongation. AFF2/FMR2, AFF3/LAF4 and AFF4/AF5q31 localize in nuclear speckles (subnuclear structures considered to be storage/modification sites of pre-mRNA splicing factors) and are able to bind RNA with a high apparent affinity for the G-quadruplex structure. They appear to modulate alternative splicing via the interaction with the G-quadruplex RNA-forming structure. Slc6a8: Creatine transporter is a protein that is required for creatine to enter the cell. Creatine is essential for maintaining ATP levels in cells with a high energy demand. GSPT2 MAGED1 UBE2A OGT
Sources: en.wikipedia.org
Cigarettes are a frequent source of deadly fires in private homes, which prompted both the European Union and the United States to require cigarettes to be fire-standard compliant. According to Simon Chapman, a professor of public health at the University of Sydney, reduction of burning agents in cigarettes would be a simple and effective means of dramatically reducing the ignition propensity of cigarettes. Since the 1980s, prominent cigarette manufacturers such as Philip Morris and R.J. Reynolds have developed fire safe cigarettes, but Phillip Morris was later the subject of a government lawsuit for allegedly hiding the even greater dangers associated with their brand of such cigarettes. The burn rate of cigarette paper is regulated through the application of different forms of microcrystalline cellulose to the paper. Cigarette paper has been specially engineered by creating bands of different porosity to create "fire-safe" cigarettes. These cigarettes have a reduced idle burning speed which allows them to self-extinguish. This fire-safe paper is manufactured by mechanically altering the setting of the paper slurry. New York was the first U.S. state to mandate that all cigarettes manufactured or sold within the state comply with a fire-safe standard. Canada has passed a similar nationwide mandate based on the same standard. All U.S. states are gradually passing fire-safe mandates. The European Union in 2011 banned cigarettes that do not meet a fire-safety standard.
In its simplest form, nutrient-enriched water is pumped into containers with plants in a growing medium such as Expanded clay aggregate At regular intervals, a simple timer causes a pump to fill the containers with nutrient solution, after which the solution drains back down into the reservoir. This keeps the medium regularly flushed with nutrients and air.
Busby WH, Quackenbush GE, Humm J, Youngblood WW, Kizer JS (1987). "An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes". J. Biol. Chem. 262 (18): 8532–6. doi:10.1016/S0021-9258(18)47446-7. PMID 3597387. Fischer WH, Spiess J (1987). "Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides". Proc. Natl. Acad. Sci. U.S.A. 84 (11): 3628–32. Bibcode:1987PNAS...84.3628F. doi:10.1073/pnas.84.11.3628. PMC 304928. PMID 3473473. Messer M; Ottesen M (1965). "Isolation and properties of glutamine cyclotransferase of dried papaya latex". C. R. Trav. Lab. Carlsberg. 35 (1): 1–24. PMID 5846578.
Impetigo herpetiformis Intrahepatic cholestasis of pregnancy (cholestasis of pregnancy, jaundice of pregnancy, obstetric cholestasis, prurigo gravidarum) Linea nigra Pemphigoid gestationis (gestational pemphigoid, herpes gestationis) Prurigo gestationis (Besnier prurigo, early-onset prurigo of pregnancy, linear IgM dermatosis of pregnancy, papular dermatitis of pregnancy, prurigo of pregnancy, Spangler's papular dermatitis of pregnancy) Pruritic folliculitis of pregnancy Pruritic urticarial papules and plaques of pregnancy (late-onset prurigo of pregnancy, polymorphic eruption of pregnancy, PUPPP syndrome, toxemic rash of pregnancy, toxic erythema of pregnancy) Striae gravidarum
MDMA is an entactogen or empathogen, as well as a stimulant, euphoriant, and weak psychedelic. It is a substrate of the monoamine transporters (MATs) and acts as a monoamine releasing agent (MRA). The drug is specifically a well-balanced serotonin–norepinephrine–dopamine releasing agent (SNDRA). To a lesser extent, MDMA also acts as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). MDMA enters monoaminergic neurons via the MATs and then, via poorly understood mechanisms, reverses the direction of these transporters to produce efflux of the monoamine neurotransmitters rather than the usual reuptake. Induction of monoamine efflux by amphetamines in general may involve intracellular Na+ and Ca2+ elevation and PKC and CaMKIIα activation. MDMA also acts on the vesicular monoamine transporter 2 (VMAT2) on synaptic vesicles to increase the cytosolic concentrations of the monoamine neurotransmitters available for efflux. By inducing release and reuptake inhibition of serotonin, norepinephrine, and dopamine, MDMA increases levels of these neurotransmitters in the brain and periphery and thereby indirectly activates the receptors of these neurotransmitters. There are species differences in the balance of MAT activities of MDMA, with it showing greater influence on serotonin in rodents than in humans. In addition to its actions as an SNDRA, MDMA directly interacts with a number of monoamine and other receptors.
Sources: en.wikipedia.org
Actually, some manufacturers of high-throughput systems have adopted the system to work with their robots. This illustrates the orientation of this kit solution to laboratories with a larger number of samples.
This is useful in drug analysis where the pharmaceutical is a combination drug since the components would separate, or elute, at different times allowing for the verification of each component. The eluates from the HPLC column are then fed into various detectors that produce a peak on a graph relative to its concentration as it elutes off the column. The most common type of detector is an ultraviolet-visible spectrometer as the most common item of interest tested with HPLC, pharmaceuticals, have UV absorbance. Gas chromatography (GC) performs the same function as liquid chromatography, but it is used for volatile mixtures. In forensic chemistry, the most common GC instruments use mass spectrometry as their detector. GC-MS can be used in investigations of arson, poisoning, and explosions to determine exactly what was used. In theory, GC-MS instruments can detect substances whose concentrations are in the femtogram (10−15) range. However, in practice, due to signal-to-noise ratios and other limiting factors, such as the age of the individual parts of the instrument, the practical detection limit for GC-MS is in the picogram (10−12) range. GC-MS is also capable of quantifying the substances it detects; chemists can use this information to determine the effect the substance would have on an individual. GC-MS instruments need around 1,000 times more of the substance to quantify the amount than they need simply to detect it; the limit of quantification is typically in the nanogram (10−9) range.
These details raise the possibility that the work was authored by a supporter of al-Hakim. However, without further investigation, the matter remains unsettled. "The Report of the Jewish and Christians" (Khabar al-Yahud wal Nasara) recounts how a delegation of Jewish and Christian representatives in Cairo, led by their religious leaders, approached Caliph al-Hakim bi-Amr Allah during one of his habitual nocturnal walks to request safety due to his policy against Christians and Jews. This encounter led to a religious debate between them. According to scholar, this meeting seems to be entirely fictional, created to support the idea that both Jews and Christians were expecting the coming of al-Hakim and Hamzah ibn Ali. Baha al-Din al-Muqtana is one of the founders of the Druze religion. Al-Muqtana's epistles comprise four of the six books of the Druze scripture, the Epistles of Wisdom. Al-Muqtana's life is largely unknown, apart from the information contained in his own writings. His name was Abu al-Hasan Ali ibn Ahmad, and he was born in the village of Sammuqa, near Aleppo in northern Syria. The familiarity with Christian theology and Christian literature exhibited in his writings suggests that he may have been originally a Christian. His numerous epistles show the extent of the Druze missionary network, which appears to have been present almost everywhere where the Fatimid-sponsored Isma'ili daʿwa was also active: Cairo and Upper Egypt, Syria, Upper Mesopotamia and Lower Mesopotamia, Persia, the Yemen, and the Hijaz.
Hemostasis occurs when blood is present outside of the body or blood vessels. It is the innate response for the body to stop bleeding and loss of blood. During hemostasis three steps occur in a rapid sequence. Vascular spasm is the first response as the blood vessels constrict to allow less blood to be lost. In the second step, platelet plug formation, platelets stick together to form a temporary seal to cover the break in the vessel wall. The third and last step is called coagulation or blood clotting. Coagulation reinforces the platelet plug with fibrin threads that act as a "molecular glue". Platelets are a large factor in the hemostatic process. They allow for the creation of the "platelet plug" that forms almost directly after a blood vessel has been ruptured. Within seconds of a blood vessel's epithelial wall being disrupted, platelets begin to adhere to the sub-endothelium surface. It takes approximately sixty seconds until the first fibrin strands begin to intersperse among the wound. After several minutes the platelet plug is completely formed by fibrin. Hemostasis is maintained in the body via three mechanisms:
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.